BRAF and neoplasm: The NCCN guidelines state that all patients with metastatic CRC should have tumor tissue genotyped for KRAS, NRAS, and BRAF mutations, and patients with any known KRAS or NRAS mutation should not be treated with anti-EGFR therapy such as cetuximab and panitumumab [18].